MiNK Therapeutics (INKT) Stock: Buy, Sell, or Hold?
INKT - MiNK Therapeutics, Inc. Common Stock
$12.44
-0.29 (-2.28%)
▼
5d:
+2.13%
30d:
+9.8%
90d:
+7.61%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When INKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INKT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INKT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INKT is currently trading at $12.44, which is considered extended relative to its 30-day fair value range of $11.40 to $12.31.
Technical Outlook: Technically, INKT is in a uptrend. Immediate support is located at $11.50, while resistance sits at $12.98.
Market Sentiment: INKT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $39.00 (+213.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INKT is in a uptrend. Immediate support is located at $11.50, while resistance sits at $12.98.
Market Sentiment: INKT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $39.00 (+213.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$11.40 -
$12.31
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 213.5% below Wall St target ($39.00)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.40 -
$12.31
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.50
Resistance Level
$12.98
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.70
Wall Street Target
$39.00
(+213.5%)
Share & Embed Analysis
Last updated: October 03, 2026 9:58 PM ET
Data refreshes hourly during market hours. Next update: 10:58 PM
Data refreshes hourly during market hours. Next update: 10:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 66 BUY |
